Carbon dioxide/perflubron

Drug Profile

Carbon dioxide/perflubron

Alternative Names: Carbon dioxide/perfluorooctyl bromide; Perflubron/carbon dioxide; S-1226

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SolAeroMed
  • Class Antiasthmatics; Fluorocarbons; Inorganic carbon compounds; Oxides; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 05 Sep 2017 Carbon dioxide/perflubron is still in phase II development for Asthma in Canada (SolAeroMed website, September 2017)
  • 13 May 2016 Safety data from a phase I trial in Asthma (In volunteers) presented at the Conference of the American Thoracic Society (ATS-2016)
  • 14 Jan 2015 Phase-II clinical trials in Asthma in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top